Lakewood-Amedex Biotherapeutics, Inc. (LABT) Fair Value 2026

LABT · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, Lakewood-Amedex Biotherapeutics, Inc. (LABT) trades at $2.49. QOC: 3.4/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
LABT
Price
$2.49
Quality Score
3.4/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.4/10 signals weak fundamentals

What Fair Value Does Each Model Give LABT?

0 Intrinsic Value Models vs. Current Price ($2.49)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Lakewood-Amedex Biotherapeutics, Inc. (LABT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lakewood-Amedex Biotherapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About LABT?

0 of 13 models are currently active for LABT. See which stocks rank higher →

How Does LABT Rank in Biotechnology?

Among 620 Biotechnology stocks, LABT ranks #577 by Quality of Company score. CirclFi's QOC score of 3.4/10 evaluates 32 fundamental signals. A score of 3.4 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Lakewood-Amedex Biotherapeutics, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating LABT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is LABT a Value Trap?

CirclFi's Value Trap algorithm assigns LABT a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Lakewood-Amedex Biotherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Lakewood-Amedex Biotherapeutics, Inc.'s fundamental quality profile registers 3.4/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LABT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lakewood-Amedex Biotherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

KLRAKailera Therapeutics, Inc.QOC 3.4AVLNAvalyn Pharma Inc.QOC 3.4ADTXAditxt, Inc.QOC 3.4CNXUConexeu Sciences Inc.QOC 3.4KARDKardigan, Inc.QOC 3.5TRAXFirst Tracks Biotherapeutics, Inc.QOC 3.4VTGNVistagen Therapeutics, Inc.QOC 6.3ALXOALX Oncology Holdings Inc.QOC 5.2CGTXCognition Therapeutics, Inc.QOC 4.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: KLRA · AVLN · ADTX · CNXU · KARD · TRAX · VTGN · ALXO · CGTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LABT?

5 companies across all industries closest to LABT’s Quality of Company score of 3.4/10.

BMMBlue Moon Metals Inc.QOC 3.4VISMVisium Technologies, Inc.QOC 3.4TGEThe Generation Essentials GroupQOC 3.4MINEMayfair Gold Corp.QOC 3.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BMM · VISM · TGE · MINE · NVDA

Where Does LABT Sit in CirclFi's Biotechnology Rankings?

LABT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Lakewood-Amedex Biotherapeutics, Inc.’s Valuation?

What is Lakewood-Amedex Biotherapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Lakewood-Amedex Biotherapeutics, Inc. (LABT). The Quality of Company score is 3.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LABT overvalued or undervalued right now?

At $2.49, 0 of 0 active models suggest LABT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Lakewood-Amedex Biotherapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.4 mean for LABT?

Lakewood-Amedex Biotherapeutics, Inc.'s QOC of 3.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on LABT?

CirclFi analyzes LABT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is LABT a value trap in 2026?

Lakewood-Amedex Biotherapeutics, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Lakewood-Amedex Biotherapeutics, Inc. (LABT) a Quality of Company score of 3.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/LABT/ · Methodology
Primary sources for this LABT valuation

Market data for LABT as of ; valuations recomputed .